Request Discount

Neuropathic Pain Market (Type - Phantom Limb Pain, Trigeminal Neuralgia, Post Herpetic Neuralgia, and Post-traumatic Neuropathy; Indication - Spinal Stenosis, and Diabetic Neuropathy; Diagnosis - Imaging Physical Examination, and Blood Tests; Treatment - Medication Type, NSAIDs Type, Antidepressant Drugs Type, and Multimodal Therapy; Distribution Channel - Retail Pharmacies and Drug Stores, and Online Pharmacies; End User - Hospitals, and Clinics): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : August, 2019

  • Rep Id : HC0639

  • Category : Healthcare & Medical Devices

  • Status : Published

This report provides exclusive insights into the COVID-19 impact on the Neuropathic Pain Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Neuropathic Pain Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Neuropathic Pain Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.

A recent report published by Infinium Global Research on neuropathic pain market provides an in-depth analysis of segments and sub-segments in the global as well as regional neuropathic pain market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional neuropathic pain market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global neuropathic pain market. According to the report, the global neuropathic pain market is projected to grow at a CAGR of 6.1% over the forecast period of 2019-2025.


Market Insight

The increasing occurrence of diabetes and cancer are the major drivers for the growth of the neuropathic pain market across the globe. Diabetes is the most common indication for neuropathic pain followed by cancer. According to the International federation diabetes federation, nearly 420 million adult population were suffering from diabetes in 2016, and it is increasing at a rate of 8.4% and is expected to reach 625 million by 2040. Furthermore, the increase in the geriatric population also fuels the growth of market growth. Furthermore, increasing awareness among patients for treatment of neuropathic pain, a rise in the demand for generic drugs, and introduction of new products for the treatment of neuropathic pain are some other factors driving the growth of neuropathic pain market. However, severe side effects of opioids and steroids and increasing prices of branded drugs are some of the factors which may hamper the growth of the global neuropathic pain market. Moreover, strong healthcare infrastructure and well-established reimbursements create an opportunity for the growth of the global neuropathic pain market in the next few years.


In terms of region, the global market for neuropathic pain has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America holds the maximum market share and is expected to dominate the neuropathic pain market during the forecast period. This is mainly due to a strong distribution network and presence of advanced healthcare infrastructure and major players in the market in the region. Furthermore, an increase in the elderly population, which leads to too many disorders and diseases are some other factors that help the growth of the market in the North American region. The European market is estimated to be the second-largest over the forecast period. This is attributed to the increasing cases of cancer patients in the region. The Asia Pacific is estimated to grow at a beneficial rate due to the growing occurrence of diabetes in countries such as China and India.


Segment Covered

The report on global neuropathic pain market covers segments such as type, indication, diagnosis, treatment, distribution channel, and end user. On the basis of type, the sub-markets include phantom limb pain, trigeminal neuralgia, post herpetic neuralgia, and post-traumatic neuropathy. On the basis of indication, the sub-markets include spinal stenosis, and diabetic neuropathy. On the basis of diagnosis, the sub-markets include imaging physical examination, and blood tests. On the basis of treatment, the sub-markets include medication type, NSAIDs type, antidepressant drugs type, and multimodal therapy. On the basis of distribution channel, the sub-markets include retail pharmacies and drug stores, and online pharmacies. On the basis of end user, the sub-markets include hospitals, and clinics.

Global Neuropathic Pain Market


Companies Profiled:

The report provides profiles of the companies in the market such as Johnson & Johnson Services Inc., Pfizer Inc., Eli Lily and Company, GlaxoSmithKline PLC, Bristol-Myers Squibb and Company, Sanofi S.A., Biogen Idec Inc., Baxter Healthcare Corporation, and Depomed Inc.


Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of neuropathic pain market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount